New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
A Phase III clinical trial has shown that a personalized mRNA vaccine, when combined with immunotherapy, reduces the risk of melanoma recurrence or death by 42 percent. The study, involving over 1,100 patients, marks a significant advancement in personalized cancer treatment.
Why it matters
This breakthrough represents a major shift in oncology, demonstrating the efficacy of individualized therapeutic vaccines in treating high-risk cancer patients.
Georgina Long, medical director of the Australian Melanoma Institute and the study’s principal investigator, said in a statement that these results are “transformative” and “have the potential to make a foundational shift in how we treat patients with earlier-stage melanoma.”
The trial, known as INTerpath-001, included 1,137 people with high-risk melanoma who had undergone surgery to completely remove their tumors. The participants were divided into two groups. Those in the first group received only Pembrolizumab, a drug that helps the immune system detect and fight cancer cells, while those in the second group were treated with the same drug in combination with the mRNA vaccine, called Intismeran Autogene.
After monitoring the participants for an average of 24.6 months, the researchers determined that addition of the vaccine reduced the risk of cancer recurrence or death by 42 percent compared to Pembrolizumab alone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in